New drug targets genetic flaw in multiple advanced cancers

NCT ID NCT04639219

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the drug trastuzumab deruxtecan (T-DXd) can help control advanced solid tumors that have specific HER2 gene mutations, regardless of where the cancer started in the body. The trial includes 102 adults with cancers like colorectal, bladder, gastric, and others that have spread and no longer respond to standard treatments. Participants receive T-DXd to see if it shrinks tumors and controls the cancer's progression.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Santa Rosa, California, 95403, United States
Research Site

Muncie, Indiana, 47303, United States
Research Site

Boston, Massachusetts, 02115, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Middletown, New Jersey, 07748, United States
Research Site

Commack, New York, 11725, United States
Research Site

Harrison, New York, 10604, United States
Research Site

New York, New York, 10021, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Anderlecht, 1070, Belgium
Research Site

Toronto, CA, M5G 2M9, Canada
Research Site

Copenhagen, 2100, Denmark
Research Site

Bordeaux, 33076, France
Research Site

Lyon, 69008, France
Research Site

Villejuif, 94805, France
Research Site

Milan, 20141, Italy
Research Site

Milan, 20162, Italy
Research Site

Naples, 80131, Italy
Research Site

Chūōku, 104-0045, Japan
Research Site

Kashiwa, 277-8577, Japan
Research Site

Suita-shi, 565-0871, Japan
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28050, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Seville, 41013, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST